載入中
NASDAQFinancial ServicesFinancial - Conglomerates
最新資料
US$10.19
US$0.00 · 0.00%
Drugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a recapitalization, or a reorganization, with one or more other entities. The company was founded in 2024 and maintains its principal office in Fort Lauderdale, Florida.
前收盤價
US$10.19
US$0.00 · 0.00%
盤中時間採用ET。市場資料可能有所延遲。
Drugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a recapitalization, or a reorganization, with one or more other entities. The company was founded in 2024 and maintains its principal office in Fort Lauderdale, Florida.
日內區間
目前US$10.19
52週區間
目前US$10.19
盤中時間採用ET。市場資料可能有所延遲。
Drugs Made In America Acquisition II Corp. currently lacks significant business operations. Its core objective is to execute a business combination, which may take various forms such as a merger, an acquisition of assets or shares, a recapitalization, or a reorganization, with one or more other entities. The company was founded in 2024 and maintains its principal office in Fort Lauderdale, Florida.
日內區間
目前US$10.19
52週區間
目前US$10.19
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 |
|---|---|---|
| 銷售、一般及管理費用 | 130.05萬 USD | 15.17萬 USD |
| 營業費用 | 130.05萬 USD | 15.17萬 USD |
| 利息收入 | 493.38萬 USD | — |
| 營業利益 | −130.05萬 USD | −15.17萬 USD |
| 淨利 | 418.71萬 USD | −15.17萬 USD |
公司資料更新於 2026年10月13日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
